Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease - Hebei Province, China, November 2018 to November 2020.
Yan Li, Pingshu Zhang, Zhijie An, Ying Ma, Yamin Wang, Liye Wang, Yunqiu Liu, Xiaodong Yuan, Keli Li, Zundong Yin, Huaqing Wang
{"title":"Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease - Hebei Province, China, November 2018 to November 2020.","authors":"Yan Li, Pingshu Zhang, Zhijie An, Ying Ma, Yamin Wang, Liye Wang, Yunqiu Liu, Xiaodong Yuan, Keli Li, Zundong Yin, Huaqing Wang","doi":"10.46234/ccdcw2023.086","DOIUrl":null,"url":null,"abstract":"<p><strong>What is already known on this topic?: </strong>Chronic obstructive pulmonary disease (COPD) exacerbations increase household economic burden, but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden.</p><p><strong>What is added by this report?: </strong>This study demonstrated the economic burden of COPD exacerbations, pneumonia, and hospitalization in COPD patients in China is substantial. Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPSV23), separately or together, were significantly associated with decreased economic burden.</p><p><strong>What are the implications for public health practice?: </strong>Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.</p>","PeriodicalId":9867,"journal":{"name":"China CDC Weekly","volume":"5 20","pages":"452-458"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/f2/ccdcw-5-20-452.PMC10236643.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"China CDC Weekly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46234/ccdcw2023.086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
What is already known on this topic?: Chronic obstructive pulmonary disease (COPD) exacerbations increase household economic burden, but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden.
What is added by this report?: This study demonstrated the economic burden of COPD exacerbations, pneumonia, and hospitalization in COPD patients in China is substantial. Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPSV23), separately or together, were significantly associated with decreased economic burden.
What are the implications for public health practice?: Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
